About Us

Mission Statement

Gene Solutions delivers unique mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies seeking to enhance their drug pipelines in the field of Central Nervous System diseases. Using our unparalleled mitochondrial genetic, therapeutic and diagnostic expertise – and fortified by our complementary UK and US science teams - we develop and validate leads, binding and cell-based assays, and companion diagnostics for some of the world’s most devastating diseases.

The Company History

Gene Solutions was founded in 2006 based on the scientific knowledge that mitochondrial gene mutations contribute to neural and muscular degenerative diseases due to the potential of multiple single point mutations occurring randomly in the mitochondrial DNA. Gene Solutions intends to utilize this knowledge to develop simple, accurate and effective clinical diagnostic methods for these diseases and to facilitate the development of therapeutic compounds The company’s aim is to diagnose and treat the underlying disease. Dr. W. Davis Parker, founder of Gene Solutions has been working in the field of mitochondrial genetic diseases for over 25 years and has identified, validated and patented the specific mutations that may be ‘causative’ of a majority of the cases of Parkinsons disease, with similar work ongoing to discover causative and reliable diagnostic mutations in other neurological diseases.

UK-Based Chemistry Discovery Research

Our discovery research efforts are headed by Drs. Brian Warrington and Davis Parker through a contract partnership with the University of Strathclyde’s Pure and Applied Chemistry leadership team, under the direction of Prof. Simon MacKay, Professor of Medicinal Chemistry, Strathclyde Institute of Pharmacy and Biomedical. Our focus is rational small molecule design directed to novel biological targets.  Gene Solutions’ oversight by the company’s scientific advisory group ensures our chemistry efforts are executed by a team of major pharma-experienced chemists and biologists with a track record in developing novel assay systems to deliver IP-protected structures with a unique mode of selective binding and molecular action at our unprecedented targets in mitochondria.